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Abstract
Imaging methods capable of indicating the potential for success of an individualized treat-
ment course, during or immediately following the treatment, could improve therapeutic
outcomes. Temperature Sensitive Liposomes (TSLs) provide an effective way to deliver
chemotherapeutics to a localized tumoral area heated to mild-hyperthermia (HT). The
high drug levels reached in the tumor vasculature lead to increased tumor regression via
the cascade of events during and immediately following treatment. For a TSL carrying
doxorubicin (DOX) these include the rapid and intense exposure of endothelial cells to
high drug concentrations, hemorrhage, blood coagulation and vascular shutdown. In this
study, ultrasound-guided photoacoustic imaging was used to probe the changes to
tumors following treatment with the TSL, HaT-DOX (Heat activated cytoToxic). Levels of
oxygen saturation (sO2) were studied in a longitudinal manner, from 30 min pre-treatment
to 7 days post-treatment. The efficacious treatments of HT-HaT-DOX were shown to
induce a significant drop in sO2 (>10%) as early as 30 min post-treatment that led to
tumor regression (in 90% of cases); HT-Saline and non-efficacious HT-HaT-DOX (10% of
cases) treatments did not show any significant change in sO2 at these timepoints. The
changes in sO2 were further corroborated with histological data, using the vascular and
perfusion markers CD31 and FITC-lectin. These results allowed us to further surmise a
plausible mechanism of the cellular events taking place in the TSL treated tumor regions
over the first 24 hours post-treatment. The potential for using photoacoustic imaging to
measure tumor sO2 as a surrogate prognostic marker for predicting therapeutic outcome
with a TSL treatment is demonstrated.
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Introduction
During cancer treatment it is normal practice to monitor the tumor for changes indicative of
treatment response. Conventionally, studies monitor volumetric changes in tumor size which
typically occurweeks after the administration of treatment and thus are not suitable as markers
of early treatment response [1]. Instead, dynamic or functional imaging techniques capable of
monitoring the relative effectiveness of drug delivery [2–5], or better still detecting the corre-
sponding therapeutic effect, during or immediately after treatment are highly sought after [6].
With this in mind, we recognized that many drugs and delivery therapies induce changes to
the tumor microenviroment long before the overall volume visibly changes, and through fur-
ther investigation it might be possible to use these for an early detectionmethod of therapeutic
effect.
TSLs are a drug delivery technology that allows the targeting of a drug payload to a localized
area through the application of mild-hyperthermia (39–42°C) [7, 8]. The release temperature
of a TSL can be tuned though the incorporation of lipids with different transition temperature
(Tm) or by adding other compounds (e.g. lyso-lipids, surfactants) to the lipid membrane. This
approach has the potential to be particularly effective in cancer treatment, where heating (and
so the drug release) can be confined to just the tumor area. This minimizes the uptake of drug
elsewhere in the body and significantly reduces any unwanted side-effects associated with che-
motherapy regimens [9]. A feature of the most clinically advanced ultra-fast temperature sensi-
tive liposomes (uTSLs) is their ability to rapidly burst-release their drug payload (in seconds)
when entering an area heated to mild-hyperthermia, but remain intact and retain the majority
of their payload (for more than an hour) at normal physiological temperatures (Fig 1). Hence,
mild-hyperthermia is usually applied within the first hour or two of uTSL treatment, for maxi-
mized concentration of encapsulated drug in circulation.
Lyso-lipid Temperature Sensitive Liposome (LTSL; DPPC/MSPC/DSPE-PEG, 86:10:4 mol
%) is an example of such a burst-release TSL formulation [9, 10], which has progressed into
late stage clinical trials delivering the drug doxorubicin (ThermoDox1, Celsion Corporation,
Lawrenceville,NJ). This formulation is currently in clinical trials for hepatocellular carcinoma
(phase III), for recurrent chest wall breast cancer (phase I/II) and for liver cancer (proof-of-
principle study). Our group has previously reported on an improved TSL formulation, HaT
(Heat-activated cytoToxic, DPPC:Brij78, 86:4 mol%), which exhibited increased release of
doxorubicin (DOX) relative to LTSL (2-fold at 40°C and 1.2-fold greater at 41°C) [11–14]. In
vivo, these release increments translated to improved tumour regression for HaT-DOX relative
to LTSL-DOX.
The mechanism of action for an ultrafast TSL has been investigated and discussed in the lit-
erature for LTSL-DOX [15, 16]. These studies suggest that the mechanism and biological
sequelae of events are different for an ultrafast TSL-DOX treatment compared to an infusion of
free DOX, when each is combined with mild-hyperthermia.More pronounced activity is
observedwith the TSL treatment, where the rapid drug release leads to high levels of DOX in
the vasculature. Subsequently, the drug attacks endothelial cells, and diffuses into the intersti-
tial space, leading to tumor cell death. In such a case, the damaged endothelial cells may no lon-
ger offer the necessary support to contain the blood and its contents. This leads to vascular
hemorrhage across the microvessel boundary, blood coagulation and vascular shutdown [11,
14]. These effects are more prominent for tumor vessels due to their inherent permeability,
structural immaturity, and high proliferation in these regions of active angiogenesis [16].
Therefore, it is hypothesized that these events could be used as an endogenous physiological
marker for an effective treatment and a potential surrogate marker of therapeutic effect. One
such marker is the tumor blood oxygenation, and we sought to investigate this parameter in
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the context of relative levels of oxygen saturation (sO2) throughout the treatment periodwith
HaT-DOX and mild-hyperthermia.
Longitudinal monitoring of blood sO2 as a function of treatment response requires an imag-
ing modality which can non-invasively monitor oxygenation with sufficient spatial resolution
and accessibility. Optical imaging techniques are capable of measuring oxygenation, but are
severely limited in their penetration depth and spatial resolution due to the dominance of bal-
listic photon scattering [17]. BloodOxygenation Level Dependent contrast (BOLD)MRI and
oxygen-enhanced (OE) MRI are the only clinical imagingmodalities capable of assessing volu-
metric tumour oxygenation [18–20]. However, these techniques are limited by their cost and
accessibility which renders them impractical for assessing the early changes in oxygenation.
Photoacoustic (PA) imaging has shown a great deal of promise in combining the most advanta-
geous features of optical modalities (contrast) and ultrasound (US) technologies (resolution)
[21–27]. Indeed, there are also recent reports correlating PA imaging data with that of the
aforementionedMRI methods.[28, 29] PA images are acquired by detecting the ultrasonic
pressure waves which are generated from the thermoelastic expansion of tissue as a result of
short laser illumination. Sweeping of the optical wavelengths of illumination allows for func-
tional PA imaging as selective absorption of the tissue chromophores would give rise to the
multiple sources of contrast contained within the PA data. In the case of oxygenation, PA
imaging has been able to compute absolute values of sO2 by taking advantage of the oxygen-
dependent optical absorption of the hemoglobin (Hb) inside red blood cells [30]. Photoacous-
tic imaging has yielded a great deal of interest over the past few years, with its ability to provide
co-registered structural and functional information on a wide variety of biomedical applica-
tions. However, most approaches have focused on engineering advances with the aim of
Fig 1. Schematic of the mode of action of a temperature sensitive liposome (TSL) for intravascular release. The TSL passes through
normal unheated vasculature intact (a), but on reaching the heated tumor (b) drug is released in a burst-release fashion, creating a high local
drug concentration which permeates into the tumor tissue.
doi:10.1371/journal.pone.0165345.g001
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improving the spatial resolution of the technique [31]. The application of PA imaging to the
treatment monitoring problem has only begun recently with several encouraging studies dem-
onstrating the potential of the technique for detecting changes of sO2 in the tumor vasculature
as a function of treatment [32] as well as during tumor development [33] and even imaging
vascular perfusion [34].
Our study utilizes PA imaging to provide new insights into understanding the mechanism
of action of the HaT-DOX TSL formulation and investigates the feasibility of PA imaging for
cancer treatment monitoring.We utilize PA imaging to map the changes in the oxygenation of
multiple slices within a murine breast cancer model in the footpad treated with our TSL formu-
lation, HaT-DOX. The efficacyof this treatment was studied relative to a saline control, and all
treatments were combined with an application of mild-hyperthermia (HT). Very early changes
in sO2 were examined for each tumour and these were correlated to the long term treatment
outcomes.
Materials and Methods
Materials
1,2-Dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) was purchased from Avanti Polar
Lipids (Alabaster, AL). Brij78 [(polyethyleneglycol-20) stearyl ether], sepharose CL-4B and
FITC-lectinwere bought from Sigma Aldrich (Oakville, ON, Canada). DOX was purchased
from Tocris Bioscience (Ellisville,MO). All other reagents were of analytical grade.
Preparation of HaT-DOX liposomes
HaT liposomes were prepared by thin lipid-film hydration followed by membrane extrusion to
control size, as described in previous reports [11, 12]. Briefly, 45 mg of lipids (DPPC/Brij, 96:4
mol%) were dissolved in isopropanol and the solvent was evaporated under a flow of nitrogen
gas at ~60°C. The resultant lipid film was dried further under high vacuum overnight to
remove any residual organic solvent. Lipid films were hydrated with 300 mM citric acid (1 mL)
to formmultilamellar vesicles, which were then extruded 21 times through polycarbonate fil-
ters (pore size: 0.1 μm) at 65°C to adjust the liposome size. Following extrusion, formulations
were cooled to room temperature and checked for size and polydispersity index (PDI) by
dynamic light scattering (DLS).
To load DOX into the liposomes, a pH gradient was used to obtain a high loading of drug
via a remote loading strategy. This method concentrates the drug into the liposome core
through the protonation and trapping of DOX upon entering the liposome core. The pH gradi-
ent was generated by first exchanging the exterior buffer with HBS (25 mMHEPES buffered
saline, pH 7.4) via dialysis (Slide-A-lyzer 10 kDaMWCO, Pierce Biotechnology, Rockford, IL).
The dialysis buffer (500 mL) was exchanged every hour for 3 hours, at which point the pH was
checked to ensure it was close to neutral. The liposome and DOX were then incubated at 37°C
for 90 min at a 20:1 ratio (w/w), respectively. Following incubation, the un-encapsulated DOX
was removed by purificationwith a sepharose CL-4B column eluting with HBS. The liposome
fractionwas analyzed for any change in size, PDI and drug content. DOX concentration was
determined using fluorescence (excitation: 485 nm; emission: 590 nm), before and after lipo-
somemembrane disruption (Triton X-100) using a fluorescence plate reader (Hidex, Finland)
as describedpreviously [11, 12]. Particle size distributions were measured by dynamic light
scattering (ZetasizerNano-ZS, Malvern Instruments Ltd, UK). All experiments were per-
formed with freshly prepared formulations.
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Cell culture and animal models
The murine breast cancer cell line EMT-6 was purchased from ATCC (Manassas, VA). EMT-6
cells were maintained in DMEM supplemented with 10% FBS, penicillin (100 U/mL) and
streptomycin (100 μg/mL) at 37°C with 5% CO2. Female BALB/c mice (aged 5–6 weeks, 18–20
g) were purchased fromHarlan (Mississauga, ON, Canada). All experimental protocols in this
study were approved by the Animal Care Committee of the University Health Network
(Toronto, ON, Canada) in accordance with the policies established in the Guide to the Care
and Use of Experimental Animals prepared by the Canadian Council of Animal Care. Mice
were housed in individually ventilated cages (up to 5 mice per cage) supplied with acidified
automatic watering system. Teklad irradiated rodent diet #7912 ad lib, autoclaved corn cob
bedding or iso-PADS beddingwas used to minimize agitation of tumors. Every cage provided
with autoclaved enrichment (a translucent, red polycarbonate house and nestlets for nest build-
ing). The animal room operates at 20–22°C, 40–70% relative humidity, with a light/dark cycle
of 12/12 hr. All animals were sacrificedwith Isoflurane anesthetic followed by CO2 asphyxia-
tion. If any signs of pain or suffering were observed then analgesics were applied. Animals were
under veterinary observation on a routine basis.
In vivo treatment protocol
The murine breast cancer cell line, EMT-6, was inoculated (1 × 106 cells/50 μL medium) subcu-
taneously into the footpad of BALB/c mice. The footpad thickness was monitored, and after
*7 days a measurable change in thickness (1.0–2.0 mm) was observeddue to tumor growth.
At this point, the mice were deemed ready to undergo the treatment/imaging protocol as
depicted in S1 Fig. Following the initial pre-treatment image, each mouse was treated with one
of the formulations: HaT-DOX (10 mg DOX/kg, n = 13) or Saline (HBS pH 7.4, n = 15), via
intravenous tail vein injection. This was immediately followed by localized heating of the
tumor-bearing hind limb footpad with a water bath at 43°C for 1 h (S1A Fig). This temperature
and time periodwas determined to be optimal for maintaining the tumor in the mild-hyper-
thermia range in previous studies [11–14]. During the treatment period,mice were anesthe-
tized with a flow of isofluorane (1.5%) in oxygen (0.5–1 L/min). Following treatment the mice
were returned to their cage and monitored closely to ensure full recovery and taken for imaging
at further timepoints as describedbelow. Mice were monitored regularly (every 1–2 days) for
changes in footpad thickness (measured by standard calipers) and body weight. Mice were
euthanized when the tumors reached double their original size (original size = treatment
day = day 0) in a single dimension, or reached endpoint via some other means (e.g. open
tumor, 20% body weight loss, immobility etc.). If a treatment showed a reduction in tumor size
at endpoint relative to the tumor’s original size at day 0, this was defined as regression. Regres-
sion rate for a particular group was defined as the number of mice that showed regression
divided by the total number of mice for each particular group.
In vivo imaging protocol
Imaging of each animal was performedwith the Vevo LAZRUS/PA small animal imaging
device (Fujifilm VisualSonics Inc., ON, Canada). This is a commercial system that consists of a
256-element, 40 MHz center frequency, linear array US/PA probe coupled to an Nd:YAG laser
operated through an optical parametric oscillator with a 6 ns pulse length, 20 Hz pulse repeti-
tion frequency and 680–970 nm output. For the purposes of this study, the tumors were inde-
pendently illuminated with 750 and 850 nm wavelengths. These two wavelengths were chosen
to probe the optical properties of blood either side of the isosbestic point (805 nm, the optical
wavelength at which the absorption of oxygenated and deoxygenated blood is the same).
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During imaging, all mice were anesthetized with a flow of isofluorane (1.5%) in oxygen (0.5–1
L/min). Clear ultrasonic gel was used to acoustically couple the footpad of each animal with the
imaging probe, while the core body temperature was maintained at ~37°C using a heating plat-
form (S1B Fig). Co-registered, 3D US and PA images were acquired by scanning the imaging
probe over the entire tumor volume (81 frames, 80 μm apart).
Imaging was performed at set timepoints before and after treatment (S1C Fig). A pre-treat-
ment image was taken 30 min prior to treatment for each animal. Each animal then received its
dose of formulation and was immediately placed in the water bath heating set-up to receive
localizedmild-hyperthermia (HT) to the tumor bearing hind limb as described above. Follow-
ing treatment, the animal was imaged at 5 further timepoints: at 30 min, 2 h, 5 h, 24 h and 7
days post-treatment.
Ultrasound and photoacoustic imaging and data processing
At each imaging timepoint, a total of 21 US/PA, 2D B-mode frames (80 μm apart) were ana-
lyzed (10 on either side of the anatomical center of the tumor determined from the US B-mode
image). Each 2D US image was used to anatomically segment the tumor in each frame, while
avoiding the skin, bone and artifacts. The same region of interest (ROI) was applied to segment
the PA images acquired at 750/850 nm for all of the 21 frames. The energy of each pulse at the
two wavelengths was measured in real-time using an energymeter (Ophir-Spiricon, North
Logan, Utah, USA) that was coupled to the image acquisition sequence.The PA images at each
wavelength were normalized by their respective, real-time energies in order to remove the
wavelength-dependent laser energy variations present within the system. The PA pressure in
tissue is directly proportional to the absorbed energy in tissue with the same constant of pro-
portionality (Grüneisen parameter) throughout tissue. Given that the tumors were small and
superficial, no corrections were made for the differences in tissue optical fluence for the two
wavelengths. Oxygen saturation (sO2) maps were generated by measuring the PA signal at 750/
850 nm for each pixel within the tumor ROI. The sO2 was calculated based on the underlying
assumption that the PA signal at the two wavelengths is primarily dominated by the optical
absorption of hemoglobin (Hb) in its oxygenated (μHbO) and deoxygenated (μHb) forms. Eq (1)
shows the derivation of the sO2 from the relationship between optical absorption and chromo-
phore concentration (oxygenated hemoglobin[HbO], or deoxygenated hemoglobin[Hb]) [35,
36],
PASAðl1Þ / maðl1Þ ¼ ½HbεHbðl1Þ þ ½HbOεHbOðl1Þ
PASAðl1Þ / maðl2Þ ¼ ½HbεHbðl2Þ þ ½HbOεHbOðl2Þ
sO2 ¼
½HbO
½HbOþHb
¼
PASAðl2Þ  εHbðl1Þ   PASAðl1Þ  εHbðl2Þ
PASAðl1Þ  Dεðl2Þ   PASAðl2Þ  Dεðl1Þ
DεðlÞ ¼ εHbOðlÞ   εHbðlÞ
ð1Þ
where, μa is the optical absorption coefficient,PASA(λ) is the photoacoustic signal amplitude at
a particularwavelength of illumination (λ), calculated as the envelope of the time-domain PA
signal within the region of interest; εHb and εHbO are the extinction co-efficients of deoxygen-
ated and oxygenated hemoglobin, respectively;Δε represents the difference in extinction coeffi-
cient between the oxygenated and deoxygenated hemoglobin. The wavelengths λ1 and λ2
correspond to 750 and 850 nm, respectively.
A schematic of the algorithm used to compute the sO2 maps and histograms is shown in S2
Fig. In order to quantify the sO2 distribution of each tumor slice, a novel approach was
employed where the sO2 intensity of all pixels within a given frame was represented in the
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form of a histogram. At each imaging timepoint, for each mouse, the average of 21 histograms
was computed along with the standard deviation of the pixel count of each sO2 value. The
resultant plot represents the temporal change in sO2 for each tumor, which were used to quan-
tify the changes in tumor sO2 as a function of time and treatment type. This approach allows
for quantification of the tumor oxygenation without relying on image processing algorithms
that might affect the estimated sO2. All image and signal processing was performed in
Matlab2014a (The MathWorks Inc., Natick, MA).
Tumor histology
For each treatment, at least 6 mice were used to study tumor histology at two key timepoints; 2
h and 7 days post-treatment. These mice were randomly pre-selected for FITC-imaging prior
to treatment with 3 mice being used for each timepoint of a particular treatment. Timepoints
were chosen to represent both a very early timepoint post-treatment and a timepoint suffi-
ciently late enough to begin to observe the early signs of treatment efficacy via conventional
tumor measurement methods. Animals used for tumor histology were injected intravenously
with FITC-lectin (0.25 mg/mL, 200 μL) following their final US/PA image and returned to
their cage. After 1 h, mice were euthanized and their footpad tumors were removed and cryo-
genically frozen in Optimal Cutting Temperature (OCT) gel for sectioning, staining and pro-
cessing by the Pathology department at the STTARR facility (Toronto, ON, Canada). Sections
were stained with H&E; fluorescent immunohistochemical stains for the vascularmarker,
CD31; and cell nuclei marker, DAPI. The sections were then scanned to identify the presence
of FITC-lectin (green channel), cyanine dye labelled CD31 Ab (red channel) and DAPI (blue
channel). Images were then processed using the Definiens software package (Munich, Ger-
many) to quantify the intensity and distribution of each stain.
Statistical analysis
All data are expressed as mean ± standard deviation (S.D.). Statistical analysis was conducted
with the two-tailed unpaired t test for two-group comparison, or one-way ANOVA, followed
by the Tukey multiple comparison test by using GraphPad Prism (for three or more groups). A
p-value of less than 0.05 was considered to be statistically significant.
Results
Characterization of HaT-DOX TSLs
The HaT-DOX liposomes were prepared as described in our earlier publications [11–13].
These liposomes were studied for size and drug loading to ensure all batches of liposomes pos-
sessed comparable physical characteristics (S1 Table). In all cases, the size observedby dynamic
light scattering was within 90–100 nm with a PDI of ~0.06. Drug loading efficiencywas gener-
ally very high (~100%) for the remote loadingmethod used, and final drug loaded liposome
concentrations were adjusted to 1 mg/mL with a drug-to-lipid ratio of ~0.05 (w/w).
Tumor efficacy for a murine footpad model
Previous studies have demonstrated improved efficacywith the HaT-DOX treatment relative
to LTSL-DOX or DOX [11–14]. In preliminary studies, the DOX fluorescence of EMT-6
tumors was measured after treatment with equal doses (10 mg DOX/kg) of each of these 3
treatments (S3 Fig). HaT-DOX showed considerably greater tumoral drug uptake, and on this
evidence, together with work from previous studies, [11–14] HaT-DOX was chosen as the TSL
for further study in this work. The therapeutic effect of the HaT-DOX (10 mg DOX/kg) and
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Saline control (sterile HBS pH 7.4) formulations were studied in a subcutaneous footpad EMT-
6 tumor model with mild-hyperthermia (HT) for a period of 1 h. Tumor size and animal body
weights were then followed to assess the relative efficacy of each treatment. All treatments that
show a reduction in tumor size at endpoint relative to day 0 were classified as showing regres-
sion. The relative tumor sizes (%) over the study periodwere plotted for each animal (Fig 2). It
is worth mentioning that many treatments underwent a transient inflammation and swelling
of the treated area for a few days post-treatment–this was particularly noticeable for many of
the HT-HaT-DOX treated mice (Fig 2A).
The HT-Saline treated mice may also have shown some inflammation although it was more
challenging to differentiate this from tumor growth. Although there was some natural variation
with each treatment, it can be seen that HT-HaT-DOX treatments generally resulted in good
tumor regression (9/10 mice showed regression over 25 days), whereas HT-Saline treatments
(Fig 2B) showed no regression, and the majority of these tumors reached endpoint by 14 days
post-treatment (tumor size 200% relative to the size on day 0). The trends are consistent with
results reported previously by our group and others for TSL and buffer control treatments
combined with mild-hyperthermia [8, 12]. None of the treatments demonstrated signs of sig-
nificant toxicity as represented by each of the animal’s changes in body weight (<10% varia-
tion) during the treatment/imaging course (S4 Fig).
Longitudinal mapping of tumor sO2
In previously unpublished preliminary work (S5 Fig), the HT-HaT-DOX treatment was stud-
ied with a window chamber tumor model indicating what appeared to be localized hemorrhage
and bleeding in the vicinity of the tumor. This not only highlighted to us an interest in imaging
a blood dependent parameter, but also provided guidance for the selection of the appropriate
timepoints for the subsequent study. Hence, the HT-HaT-DOX and HT-Saline treated animals
in this study were imaged at several timepoints using non-invasive, co-registered ultrasound
Fig 2. Tumor growth plots for mice treated with 1 hour of hyperthermia (HT) and an intravenous dose of
(a) HaT-DOX (n = 10) or (b) Saline (n = 12). Tumors were grown subcutaneously in the footpad of the right hind
limb and changes in size were measured regularly with calipers. HT-HaT-DOX treatments were dosed at 10 mg
DOX/kg. The dashed line (- - - - -) represents the endpoint due to tumor load. The † symbol indicates mice which
reached a premature endpoint due to tumor ulceration or lack of sufficient mobility. The f symbol indicates all mice
that were sacrificed for histology at 7 days post-treatment.
doi:10.1371/journal.pone.0165345.g002
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and photoacoustic methods in order to test the hypothesis that sO2 might be a surrogate prog-
nostic marker for effectiveHT-HaT-DOX treatment.
The sO2 maps derived from two-wavelength photoacoustic imaging of tumors represent the
relative spatial distribution of oxygen saturation within the tumor (S6 Fig). A time-dependent
change of sO2 was observed for the HT-HaT-DOX group and to demonstrate this visually the
overall trend of the group can be represented nicely in just a few imaging timepoints from one
of these animals (Fig 3). Each 2D map denotes the sO2 of blood inside the segmented tumor
ROI at 30 min pre-treatment, and 2 h and 7 days post-treatment. For HT-HaT-DOX treated
mice, a significant drop in the tumor sO2 was observed at 2 h post-treatment compared to the
30 min pre-treatment image. At 2 h post-treatment, while some bloodwithin the tumor still
contained moderate to high sO2 values (orange/red colour in Fig 3), the majority of the tumor
exhibited very low sO2 (blue colour in Fig 3). It is important to note that the significant drop in
the tumor sO2 for the HT-HaT-DOX treated mice was apparent as early as 30 min post-treat-
ment and it remained at these levels for more than 5 h (S6 Fig).
The HT-Saline group received injections of HBS (pH 7.4) prior to undergoing an identical
mild-hyperthermia treatment protocol to the other animals that received drug formulation.
The sO2 for the HT-Saline group did not show the decrease in sO2 observed for the HT-HaT-
DOXmice at 2 h post-treatment (Fig 3, bottom row). For the specificHT-Saline treated mouse
represented in this figure, the sO2 shows a slight increase from the 30 min pre-treatment time-
point to the 2 h post-treatment timepoint image, as represented qualitatively by the increase in
red and decrease in blue colour in the image.
The trends represented in Fig 3 were consistent across each respective group, i.e. HT-HaT-
DOX treatment led to an immediate drop in tumor sO2 which was sustained for at least the
first 5 h post-treatment, while for HT-Saline no such drop in sO2 was observed and levels
remained relatively constant for the same periodwith minor fluctuations (S6 Fig). Upon reach-
ing the 7 day timepoint both groups exhibited a similar behaviour, where the overall sO2 rose
above the level observed for their respective 30 min pre-treatment images.
Oxygen saturation (sO2) histograms and quantification of the changes in oxygen-
ation. In order to quantify the relative sO2 of the blood in tumors and capture the heteroge-
neity of the entire tumor volume, histograms of the distribution of sO2 values (number of
pixels with a certain sO2 value as a function of that sO2 value) were calculated (Fig 4). The his-
togram of every imaging slice was combined to create an average histogram representing a
Fig 3. Representative sO2 maps, These are shown for HT-HaT-DOX (top row) and HT-Saline (bottom row) treated tumors at 30 min pre-
treatment (1st column), 2 h post-treatment (2nd column) and 7 days post-treatment (3rd column). The scale bar (2 mm) and sO2 color bar (0–100%)
apply to all sO2 maps shown.
doi:10.1371/journal.pone.0165345.g003
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treatment group at a given timepoint (30 min pre-treatment and at 30 min, 2 h, 5 h, 24 h and 7
days post-treatment, S2 Fig).
Regardless of the timepoint or treatment type, all histograms showed a distribution of sO2
values. The histogram of the HT-HaT-DOX treated animals revealed a significant shift to the
left during the first few timepoints, representing a drop (>15% in histogrammode) in oxygen
saturation (Fig 4A). This shift was apparent as early as 30 min post-treatment and it persisted
Fig 4. Oxygenation histograms. (a) Average sO2 histograms at 30 min pre-treatment and 30 min, 2 h, 5 h, 24 h and 7 day timepoints post-
treatment for HT-HaT-DOX (n = 12) and HT-Saline (n = 15). Two timecourses have been plotted to compare the treatments studied using the mode
(b) and mean (c) averages of the histogram data plotted in (a) relative to their starting values at 30 min pre-treatment. Error bars represent the
standard deviation on the pixel count for each sO2 value from each mouse which had 21 different histograms per imaging timepoint. The black
arrows represent the points at which the treatments were made (i.e. defined in this plot as 0 h). Datapoints that show a drop in sO2 which is
significantly different to pre-treatment are represented by * where p < 0.05.
doi:10.1371/journal.pone.0165345.g004
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for the first 5 h, in agreement with the sO2 map images (Fig 3 and S6 Fig). The histogram
shifted to higher sO2, approaching that of pre-treatment levels by 24 h, and by 7 days it had
surpassed the values of the pre-treatment histogram. This dynamic shift in the distribution of
blood sO2 values within the tumor was quantitatively represented by the early drop (30 min to
5 h post-treatment) and late (7 day) increase in tumor sO2 observed following HT-HaT-DOX
treatment.
Histograms for the HT-Saline group exhibited comparable 30 min pre-treatment sO2 distri-
butions to the HT-HaT-DOX group (modes ~ 40%). However, there was no significant drop in
the average sO2 (either mean or mode) during the first 5 h post-treatment, and again an
increase was observedby 7 days post-treatment. In general, the post-treatment histograms of
the HT-Saline group appeared to have broader distributions and displayed increased bimodal
character (e.g. 2 h histogram for HT-Saline in Fig 4A), than observed for the HT-HaT-DOX
group.
Given that a distribution of sO2 values exists within the tumor, one must quantify the
changes in the sO2 over time by focusing on the statistics of the histograms. The mode of the
sO2 within the tumor, represented by the peak of a histogram, can be representive of how the
sO2 distribution varies over time, and this is particularly effective for HT-HaT-DOX, but this is
less meaningful for the broad distributions for the HT-Saline treatment, particularly when
bimodal character is observed. For this reason, we studied both the mode and mean sO2 change
over time (Fig 4B and 4C). For the HT-HaT-DOX treated mice, a significant drop in the mean
(~10%) and mode (~15%) of the histogram was observed from 30 min pre-treatment to 30 min
post-treatment. This is indicative of an overall shift of the entire tumor region to reduced sO2
after treatment, and is visually represented as a shift of the entire histogram distribution to the
left (Fig 4A). The drop in the mean sO2 value was sustained for the first 5 h. Following this ini-
tial period, a gradual increase in mean and mode sO2 for HT-HaT-DOX was observeduntil
day 7, reaching levels 15–20% above those at 30 min pre-treatment.
The changes in mode and mean of the sO2 histogram for the HT-Saline group (Fig 4B and
4C) were quite different to those of the HT-HaT-DOX group over time. The histogrammode
showed very little change from pre-treatment during the first 5 h post-treatment. The mean
sO2 also variedmuch less than for HT-HaT-DOX but showed a slight increase (2–3%) in sO2
over the first 5 h post-treatment relative to pre-treatment. By the 7 day timepoint, the mean
sO2 had increased to ~10% above pre-treatment levels.
Correlation between early changes in sO2 and treatment efficacy
The relationship between the change in tumor size (at endpoint relative to day 0) and the
change in the mean sO2 (at 2 h post-treatment relative to 30 min pre-treatment) was plotted
for the mice of both treatment groups (Fig 5). From analysis of the HT-HaT-DOX group there
was a significant separation between the mice which showed regression and the one that did
not. The mice that responded to treatment exhibited a decrease in tumor size of at least 50% by
their endpoint and their mean sO2 at 2 h had dropped by an average of 10–15% from 30 min
pre-treatment values. This figure demonstrates how a large drop (>10%) in mean sO2 at 2 h
post-treatment was typically correlated with a large tumor regression by endpoint. The major-
ity (90%) of animals from the HT-HaT-DOX group are contained within one standard devia-
tion of the mean. The HT-Saline treated mice did not show such a clear trend as represented
by the wide distribution of data points and larger standard deviation on both axes.
A single HT-HaT-DOX treated mouse (marked † in Fig 5) did not show the characteristic
drop in sO2 of more than 10% by 2 h post-treatment as observed for the other HT-HaT-DOX
treated animals. In fact, this treatment displayed no significant decrease in sO2 throughout the
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first 5 h post-treatment. Furthermore, no regression was observed for this particular treatment,
with the tumor increasing in size to>200% in just 7 days.
Histological analysis of tumor treatment
To investigate the cause for the observed changes in sO2, a second experiment was performed
where animals were sacrificed at two distinct timepoints post-treatment (2 h and 7 days) fol-
lowing treatment with mild-hyperthemia and either HaT-DOX or Saline. These timepoints
were chosen in order to represent the key changes observedwith PA imaging.
Sections of HT-HaT-DOX treated tumor showed significant FITC-lectin perfusion and
leakage from the vasculature at the 2 h timepoint (Fig 6A and 6C). This level of FITC leakage
was not observed for the HT-Saline group at 2 h or 7 days (Fig 6B and 6D), nor for the
HT-HaT-DOX treated mice at 7 days post-treatment. The area of FITC positive tumor was
analyzed with Definiens software to provide quantitative results (Fig 6E and 6F), demonstrat-
ing an average area of ~ 60% FITC positive tumor for the HT-HaT-DOX mice at 2 h, while
only 20–40% was observed for all timepoints with the HT-Saline treated animals. The level of
vessel perfusionwas also studied and showed a similar trend between treatments and time-
points (S7 Fig). This data also correlates well with observations using the window chamber
model (S5 Fig) with significant FITC-leakage/bleedingobserved in both cases at the 2 h post-
treatment timepoint.
Discussion
There is a need for chemotherapies that are localized in their action; this could provide a
means of limiting toxicity to normal tissue and improve the therapeutic window of the drugs
involved [37]. Triggered release nanoparticles provide one way this could be achieved [38–40],
an example of which are TSLs [7]. Regardless of the treatment type, emerging evidence suggests
Fig 5. Size and oxygenation relationships. Correlation between the changes in the size of the tumor treated with (a) HT-HaT-DOX and (b)
HT-Saline at endpoint (from day 0) and the changes in mean sO2 between the values observed for 30 min pre-treatment and 2 h post-treatment.
Each point is the average of 21 sO2 histograms at the 2 h timepoint. The major and minor axes of each ellipse represent the standard deviations of
the change in sO2 and change in tumor size, respectively. † identifies a datapoint for a HT-HaT-DOX treatment that did not show regression, nor a
characteristic drop in sO2 at 2 h post-treatment.
doi:10.1371/journal.pone.0165345.g005
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that early assessment of therapeutic effect has the potential to have a significant clinical impact
[17, 41–45]. The early readout of treatment efficacy could potentially be achieved directly
throughmeasurements of relative levels of endogenous biomarkers [46, 47]; an approach
which is warranted by the complex nature of cancer growth and treatment response that
requires personalized therapies as well as personalizedmeans of assessing treatment outcome
[47]. Even with the impressive advancements in personalizedmedicine and nanotechnology,
current practice for assessment of cancer treatment efficacy is often limited to the anatomical
information obtained through imaging studies using magnetic resonance or computed tomog-
raphy. These methods can be prohibitively costly, often require the use of contrast agents with
lengthy scan times, and most commonly measure the change in tumor size which may not be
apparent until weeks after treatment. The motivation for this study stemmed from the desire to
assess therapeutic effect shortly after treatment (< 6 h) in order to make reasonable estimates
of treatment prognosis and potential success on a personalized level.
Here, we have studied a TSL developed in our lab (HaT-DOX), designed to release its pay-
load at mild-hyperthermia (HT, 39–42°C), and probed the tumor region in vivo with US-
guided PA imaging throughout the course of the treatment period (from 30 min pre-treatment
Fig 6. Tumor histology. Representative sections of footpad tumor harvested at the 2 h timepoint and stained with CD31 (red), DAPI (blue) and FITC-
lectin (green) for (a) HT-HaT-DOX, and (b) HT-Saline treated mice. The same sections displaying the regions defined as FITC-positive tumor (green),
FITC-negative tumor (orange) and normal tissue (maroon), after processing with Definiens software for (c) HT-HaT-DOX and (d) HT-Saline. Column
scatter plots: Relative FITC-postive areas following quantification with a Definiens analysis at (e) 2 h and (f) 7 days post-treatment; Significance is
represented by * where p < 0.0005.
doi:10.1371/journal.pone.0165345.g006
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to 7 days post-treatment).We sought to demonstrate improved treatment efficacywith the
HaT-DOX formulation over that of Saline when each was combined with mild-hyperthermia.
In addition to demonstrating therapeutic effect, we also investigated the structural and func-
tional changes taking place within the tumor during and following treatment, by using the
non-invasive methods of ultrasound (US) and photoacoustics (PA).
HaT-DOX TSLs were prepared in a similar manner to that describedpreviously [12, 13],
and studied with a tumour footpad model, allowing the application of mild-hyperthermia
(43°C) localized to just the tumor-bearing hind limb. In doing so, drug delivery was targeted to
the tumor region and compared with Saline (HBS pH 7.4) control using the same mild-hyper-
thermia heating method (HT). HT-HaT-DOX showed good efficacywith 90% of tumors dem-
onstrating significant regression by endpoint. Meanwhile the HT-Saline treatment was
essentially ineffective, with no treatments displaying regression. These data closely match
responses observed in previous reports with this formulation [12] and other related intravascu-
lar “burst-release” TSLs [48]. It is worth noting that while tumor inflammationmost likely
influenced absolute measurements of tumor volume in the first 3–10 days post-treatment, but
this had no affect on the relative change at the study endpoint necessary to classify tumor
response.
After demonstrating the differences in therapeutic effect, our study investigated the poten-
tial of US-guided PA imaging for non-invasive cancer treatement monitoring. PA imaging is
relatively new to this field, but it offers a great deal of promise in being able to provide co-regis-
tered functional and structural information without any endogenous contrast [33, 49]. Within
the resolution limits of our imaging system (45 μm axial, 90 μm lateral), PA imaging was capa-
ble of capturing the oxygenation of the blood up to a depth of 11 mm at 40 MHz. At lower fre-
quencies, PA has even been shown to map the location of vessels as deep as 40 mm in breast
tissue [50]. The added spatial resolution at clinically relevant depths yields a distinct advantage
of PA imaging over other optical methods that are limited to sub-micron depths due to ballistic
photon scattering [25].
Based on preliminary window chamber data (S5 Fig), prior studies, and the proposed TSL
mechanism of action (vide supra), it was hypothesized that the drug induced damage to the
vasculature and tumor tissue could lead to the entrapment of deoxygenated red blood cells
(known as blood pooling) in the perivascular space of the HaT-DOX treated tumors. These
deoxygenated red blood cells would likely remain in this state until injury repair mechanisms
start to regenerate the treatment area. Hence, during this period it should be possible to observe
a distinct drop in oxygen saturation (sO2) for all successful TSL treatments and this would be
detectable with non-invasive PA imaging. Therefore, imaging timepoints ranging from 30 min-
utes to 7 days post-treatment were chosen based on the preliminary window chamber data col-
lected, and the prior work on the mechanism of TSL drug action on the tumor vasculature [8].
The potential for using the change in the sO2 as a surrogate marker for therapeutic effect fol-
lowing TSL treatment was investigated. Following treatment with the TSL HaT-DOX, we
found a strong correlation between the early changes in the sO2 of a tumor, and the change in
tumor volume in the longer-term.While the sO2 maps for both the HT-HaT-DOX and HT-Sa-
line treated mice appeared very similar at 30 min pre-treatment, there was a clear change
between the two groups at the 30 min post-treatment timepoint. At this early timepoint, the
mode of the sO2 values was seen to drop significantly (~10–20%) for the HT-HaT-DOX treated
mice, but not for the HT-Saline group; an effect that lasted for up to 5 h post-treatment. The
drop in sO2 for the HT-HaT-DOX treatment correlated well with a significant tumor regres-
sion (90% regression rate) 28 days post-treatment. No such drop in sO2 or tumor regression
was observed for the HT-Saline treatment, indicating the significance of the HaT-DOX compo-
nent. To the best of our knowledge this is the first time an imagingmodality has been used to
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study the effect of a TSL on the tumor environment in order to predict the long term therapeu-
tic outcome.
The proposedmechanism for an ultrafast burst-release TSL (such as HaT-DOX) provides
sufficient information to account for the significant drop in sO2 observed for the HT-HaT-
DOX treated tumors between 30 min to 5 h post-treatment, as well as agreeing with the histo-
logical data obtained. Once vessels are disrupted due to the physiological effects of the
HT-HaT-DOX treatment (likely more pronounced for the neo-vascularture of the tumor
region), their ability to circulate oxygenated red blood cells is diminished, resulting in a drop of
tumor sO2 levels (Fig 7). The high concentrations of DOX released inside the tumor vascula-
ture leads to damage of both endothelial and tumor cells as the drug rapidly permeates out of
the vessels and into the surrounding tissue, aided by the damaged vasculature as demonstrated
by the increased levels of FITC-lectin observed for these tumors (Fig 6) and significant hemor-
rhage within the tumor (as observed in the preliminary window chamber study (S5 Fig). The
observed low sO2 environment persists for more than 5 h, after which a gradual increase in
tumoral sO2 starts to be observed.During this time, the natural repair mechanisms of the body
will be prevalent, leading to recruitment of macrophages and immune cells for clean-up and
regeneration of the damaged vasculature and surrounding tissue [51]. This was observed as a
transient inflammation and swelling of the treated area for the first few days post-treatment.
Approximately three to ten days later this inflammation had begun to subside and it appeared
the vasculature had been repaired, accounting for the increase in sO2 observed at 7 days. These
findings are further supported by the relatively small changes in tumor size over the first week
for the HT-HaT-DOX group, which could also be explained by such inflammation and tissue
regeneration.
Unlike the HT-HaT-DOX group, the HT-Saline group showed no regression, very little
change in sO2 (30 min to 5 h post-treatment, Fig 4) and in most cases a significant increase in
tumor size was observed.However, much like the HT-HaT-DOX group, by 7 days the HT-Sa-
line group also showed a significant increase in sO2. In this case we speculate that the increase
is due to the recruitment of new vessels required to maintain tumor growth. Consequently, the
key difference observed in this study between the HT-HaT-DOX and HT-Saline groups
remains the drop in sO2 observed for HT-HaT-DOX within the first 5 hours after treatment,
which corresponded to the desired therapeutic effect. In future work, it would be of interest to
Fig 7. Proposed mechanism and levels of oxygen saturation (sO2) following treatment with a burst-
release TSL such as HaT-DOX triggered with mild-hyperthermia. The timecourse is represented as a number
of snapshots which appear sequentially from A-E.
doi:10.1371/journal.pone.0165345.g007
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further investigate the mechanism of action by computing the total hemoglobin concentration
as a function of time. Utilizing spectral unmixing approaches[52] might elucidate the upcon-
version of oxyhemoglobin to its deoxygenated counterpart and provide further evidence of vas-
cular shutdown due to HT-HaT-DOX.
From studying the distribution of results expressed as change in tumor size (day 0 to end-
point) versus change in mean sO2 (30 min pre-treatment to 5 h post-treatement) a clear segre-
gation between efficacious and non-efficacious treatments was observed.We propose that with
furtherwork a threshold sO2 drop could be identified, which would represent the “cut-off”
drop in sO2 required for a treatment to show significant tumor regression. For example, in the
current study a single HT-HaT-DOX treated animal may have been identified as an ineffective
treatment; not reaching a threshold drop in sO2 and also not demonstrating a characteristic
tumor regression response (Figs 2 and 5). Treatment response is affected by a wide array of fac-
tors that stem from ineffective delivery of the targeted therapeutic payload, to biological vari-
ability in the tumor’s biology [53]. In the case of this HT-HaT-DOX treated animal, the tumor
grew to 200% of its original size in 2 weeks, while the mean change of the sO2 histogrammean
between 30 min and 2 h post-treatment was not significantly different to values recorded pre-
treatment (p not less than 0.05). It is encouraging that this HT-HaT-DOX treated animal,
which showed no regression, also did not reach the threshold sO2 that this work suggests is
necessary for a therapeutic response. This reinforces our hypothesis that sO2 has the potential
to be used as a predictor of therapeutic effect for ultrafast TSL treatments like HaT-DOX. The
results of this study suggest that there is indeed added value to probing the tumor sO2 at depths
that are clinically meaningful and may not be reached by means other than PA imaging.
As PA imaging begins to make its transition into the treatment monitoring arsenal, it is
encouraging to see that other treatment types, (namely photodynamic therapy, antiangiogenic
approaches or novel vascular strategies for augumentation of radiation therapy) are capable of
inducing changes in tumor vasculature that might also be detectable with PA imaging. As Mal-
lidi and colleagues demonstrate in their recent study, treatment response following photody-
namic therapy was strongly correlated with a significant drop in sO2 several hours post-
treatment [32]. Our current study builds on the findings of that work, as we demonstrate that
PA imaging of oxygen saturation is able to predict the therapeutic effect of a burst-release TSL
just a few hours post-treatment.We believe that our work, combined with that of others, high-
lights the considerable potential of PA imaging for the rapid assessment of such treatments at a
personalized level.
Conclusion
This work provides the first example of the use of PA imaging for predicting the therapeutic
effect of an ultrafast burst-release TSL treatment, though the study of endogenous sO2 values
between 30 min to 5 h post-treatment. Our TSL (HaT-DOX) was studied with mild-hyperther-
mia (HT) and demonstrated a significantly improved therapeutic effect (regression rate of
90%, n = 10), relative to HT-Saline (regression rate: 0%, n = 12). Simulataneously, HT-HaT-
DOX and HT-Saline treatments were probed with US-guided PA imaging and a significant
drop in sO2 (>10%) was observed for every treatment that demonstrated tumor regression by
experiment endpoint (i.e. 90% of HT-HaT-DOX treatments). No such drop in sO2 was
observed for any HT-Saline treatment; nor the single HT-HaT-DOX treatment that showed no
regression following treatment. From this data, we suggest a threshold sO2 drop can be identi-
fied which would be necessary to achieve an effective treatment, and through further investiga-
tion, we anticipate this methodology could provide a reliable means for predicting therapeutic
outcome within the first few hours of TSL treatment.
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Supporting Information
S1 Fig. Schematic representation of the experimental set-ups. (a) The TSL treatment water
bath, (b) the US/PA imaging configuration and (c) a schematic of a representative treatment
and imaging timecoursewith imaging timepoints indicated on the x-axis.
(TIF)
S2 Fig. Schematic showing the process for generating tumor sO2 maps and histograms. (a)
US image of a mouse footpad tumor used for anatomically segmenting the tumor ROI; (b) ROI
is applied to the PA images acquired from the 750 nm (top) and 850 nm (bottom) illumina-
tions; (c) The sO2 map is reconstructed using the algorithm described in section 2.6; (d) Oxy-
gen saturation histograms were created from the sO2 map data for 21 2D slices within a given
tumor.
(TIF)
S3 Fig. Fluorescentmicroscopy of tumors treated with HaT-DOX, LTSL-DOX and DOX.
Each treatment dosed i.v. (10 mg DOX/kg) and exposed to 1 h of mild-hyperthermia. Follow-
ing this, tumors were removed, sectioned and nuclei were stained with DAPI. Sectionswere
then studied by fluorescent microscopy to ascertain the relative amounts of DOX present in
each tumor.
(TIF)
S4 Fig. Body weight plot for the 2 formulations studied.Animals were dosed with either
HaT-DOX or Saline and treated with mild-hyperthermia (1 h). Data points are the average of 5
or more animals ± S.D.
(TIF)
S5 Fig. Window chambermodel of HaT-DOX treatments.During our previous investiga-
tions into the HaT-DOX treatment we studied a window chamber model and observedwhat
appeared to be localized hemorrhage and bleedingwithin the tumor area at 2h following treat-
ment with HT-HaT-DOX. From the timepoints we studied, it appeared that this effect
occurredwithin the first few hours post-treatment. This not only gave us good reason to
explore these early timepoints post-treatment, but also suggested that suitable markers for
detection of this effect could be something related to the blood–the oxygen saturation of hemo-
globin (sO2) appeared to be a suitable endogenousmarker, which could be studied quantita-
tively with non-invasive PA imaging.
(TIF)
S6 Fig. Representative sO2 maps for mice whose endpoint was greater than 7 days. The 
denotes the HaT-DOX-treated mouse that did not respond to treatment and whose tumor
grew 100% in size. The scale (2 mm) and color bar (0–100%) apply to all images.
(TIF)
S7 Fig. Assessments of vessel perfusion.Vessel perfusion for the HT-HaT-DOX treatment is
indicated by the white arrows in the magnified image (a), where the overlap of FITC and CD31
appears yellow. Relative number of FITC-perfusedvessels following quantification with a
Definiens analysis at (b) 2 h and (c) 7 days post-treatment. Significance is represented by 
where p< 0.0005.
(TIF)
S1 Table. Physical parameters of the HaT-DOX liposomesused in this study. Values are
mean ± S.D.
(TIF)
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